Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
Public ClinicalTrials.gov record NCT01179737. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this trial was to establish the safety, tolerability and PK of nilotinib in this population and to test the hypothesis that 6 months treatment with nilotinib will significantly reduce pulmonary artery resistance.
Study identification
- NCT ID
- NCT01179737
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2010
- Primary completion
- Dec 31, 2012
- Completion
- Dec 31, 2012
- Last update posted
- Apr 30, 2014
2010 – 2013
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Boston | Massachusetts | 02118 | — |
| Novartis Investigative Site | Ann Arbor | Michigan | 48109-0391 | — |
| Novartis Investigative Site | Chapel Hill | North Carolina | 27599 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44195 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37232-2573 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
Recently updated Pulmonary Arterial Hypertension trials
Other public records listing Pulmonary Arterial Hypertension. Sorted by last update posted; newest first. Not a recommendation.
- NCT01712620: Spironolactone for Pulmonary Arterial Hypertension Recruiting
- NCT07781709: UNDERSTANDING THE EFFECTS OF PULMONARY ARTERIAL HYPERPTENSION ON LEAN MUSCLE MASS-SUBSTUDY Not yet recruiting
- NCT07143448: A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults Recruiting
- NCT06992440: Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension Recruiting
- NCT04991454: Xenon MRI Pulm Hypertension Recruiting
- NCT07751120: Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in PAH. Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01179737, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 30, 2014 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01179737 live on ClinicalTrials.gov.